Previous Article | Next Article ![]()
Molecular and Cellular Biology, August 2004, p. 7197-7205, Vol. 24, No. 16
0270-7306/04/$08.00+0 DOI: 10.1128/MCB.24.16.7197-7205.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Sandra W. Leung, Vittoria Criniti, Monica Agromayor, and Lili Yamasaki*
Department of Biological Sciences, Columbia University, New York, New York 10027
Received 26 January 2004/ Returned for modification 23 March 2004/ Accepted 26 May 2004
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
To understand the role of E2F/DP complexes in vivo, we and others have constructed mutant mice lacking one or more of these family members. Six of the genes encoding E2F family members have been inactivated in mice, leading to a wide range of tissue-specific phenotypes. E2f1 deficiency leads to increased tumor predisposition and tissue atrophy (4, 27). When combined with E2f1 deficiency, E2f2 deficiency causes abnormal maturation of multiple hematopoietic lineages (11), similar to what is observed with E2f4 deficiency alone (8, 19). E2f3 deficiency results in reduced viability and congestive heart failure (9). Since the combined deficiency of E2f1, E2f2, and E2f3 prevents the proliferation of primary mouse embryonic fibroblasts, E2F/DP complexes involving these family members are required for normal development (25). Loss of E2f5 or E2f6 results in highly restricted phenotypes, abnormal choroid plexus function, and homeotic transformations of the axial skeleton, respectively (12, 21).
In sharp contrast to the milder phenotypes resulting from the inactivation of the E2f family members, we have demonstrated that loss of Dp1 results in the death of all embryos prior to embryonic day 12.5 (E12.5) (10). Dp1 deficiency greatly impairs the development of trophectoderm-derived tissues, resulting in placental insufficiency, which secondarily leads to embryonic death. Loss of Dp1 severely compromises DNA replication in the ectoplacental cone and the extent of endoreduplication occurring in trophoblast giant cells, results that are consistent with the known roles of E2F/DP complexes in stimulating S-phase entry and completion. The inability of DP2 to compensate for the loss of DP1 is likely due to the low level of expression of DP2 in the extraembryonic compartment. The severity of the Dp1-deficient defect (early lethality and its complete penetrance) is consistent with the observations that Dp1 is the most highly expressed family member and activation and repression by E2F/DP complexes depends completely on the presence of the DP proteins.
To define the roles of Dp1 in the embryo proper, we first generated Dp1-deficient embryonic stem (ES) cell lines carrying the ROSA26 promoter-LacZ reporter (5), which allowed us to follow the contribution of Dp1-deficient cells into embryonic tissues by staining with X-Gal (5-bromo-4-chloro-3-indolyl-ß-D-galactopyranoside). To bypass the extraembryonic requirement for Dp1, these Dp1-deficient ES cells were injected into wild-type blastocysts to allow the development of the Dp1-deficient chimeric embryos. Surprisingly, these experiments have demonstrated that, in most tissues, Dp1 is dispensable for normal development.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Genomic PCR genotyping. Genotyping at the Dp1 locus was performed by using genomic PCR in combined reactions as previously described with the common primer L75 and the unique primers L78 and L79 (10).
The presence or absence of the LacZ reporter at the ROSA26 locus was detected by genomic PCR with the common L221 primer and the unique primers R316 and L238, which are specific to the wild-type ROSA26 locus or the LacZ transgene, respectively. To improve the reliability of the ROSA26 genotyping assay, we sequenced the ROSA26 locus and designed the L221 ([5'-CTTGTGATCCGCCTCGGAGTATT-3']) and L238 ([5'-CGCGCCGCTGTAAAGTGTTACGT-3']) primers to shorten the length of the PCR products to 186 bp (wild-type allele) and 400 bp (LacZ trapped allele). A description of the R316 primer ([5'-GGAGCGGGAGAAATGGATATG-3']) was previously published (28). Amplification was performed with annealing at 54°C for 34 cycles and then visualized on a 1.6% agarose gel with ethidium bromide.
Generation and implantation of Dp1-deficient chimeric embryos. Wild-type C57BL/6 females were mated to C57BL/6 stud males, and vaginal plugs were detected the next morning (0.5 days postcoitum). The uterine horns of these pregnant C57BL/6 donor females were flushed with M2 medium to collect blastocysts (at 3.5 days postcoitum). Logarithmically growing ES cells with a minimum of gamma-irradiated embryonic feeders were treated with trypsin and resuspended in ES-DMEM, supplemented with HEPES (pH 7.0). Blastocysts were then injected with 10 to 15 ES cells per blastocyst. Manipulated blastocysts were allowed to recover in M2 medium at 37°C in a CO2 incubator and were then reimplanted into the uterine horns of pseudopregnant CD-1 recipient females as described previously (16). After various times of additional gestation, the pregnant recipients were sacrificed, and chimeric embryos were dissected away from deciduas and placenta and then processed for either whole-mount analysis or cryosectioning. All animals were maintained in a pathogen-free, barrier facility with the oversight of the institutional veterinarian and Columbia's Institutional Animal Care and Use Committee.
X-Gal staining of ES cells, whole-mount embryos, and cryosections. For staining ES cell colonies, feeder layer-bound colonies were rinsed in phosphate-buffered saline (PBS), fixed briefly in 4% paraformaldehyde, rinsed in PBS again, and then incubated in X-Gal staining solution [20 mM MgCl2, 0.2% NP-40 (Calbiochem), 50 mM K3Fe(CN)6, 50 mM K4Fe(CN)6, and 1 mg of X-Gal (LabScientific, Inc.)/ml in PBS] overnight at 37°C to detect ß-galactosidase activity.
For staining of whole-mount embryos, embryos were collected from pregnant recipient females, fixed in 10% buffered formalin (hemisected for embryos older than E12.5), rinsed in PBS, and incubated in staining solution overnight at 30°C. For cryosections, embryos were collected, fixed in 2% paraformaldehyde in PBS for several hours, hemisected, fixed longer, and then rinsed in PBS and equilibrated in 18% sucrose in PBS overnight at 4°C before sectioning on positively charged slides. The embryonic cryosections (10 µm) were then incubated overnight in staining solution at 30°C, counterstained in Nuclear Fast Red (Vector Laboratories), dehydrated through a graded series of methanol, and mounted with Permount.
Western blotting of ES cell lysates and Dp1-deficient chimeric organs. ES cell lines were grown without feeders for several days and then treated with trypsin, and the cell pellets were collected and lysed in 2x Laemmli buffer with two rounds of sonication and boiling. Microdissected organs were collected and frozen from two Dp1-deficient chimeric embryos (29A and 29C) and two Dp1+/+ C57BL/6 embryos at E15.5. For Fig. 4A, organs were lysed with 2x Laemmli buffer by multiple rounds of sonication and boiling. For Fig. 4B and C , organs were lysed in TRIzol (Invitrogen), which allowed the recovery of RNA and protein according to the manufacturer's instructions. Total protein was solubilized in 2x Laemmli buffer with sonication and boiling. An approximately equal amount of total protein (estimated by Coomassie blue staining for each lysate) was separated by sodium dodecyl sulfate-10% polyacrylamide gel electrophoresis and then transferred to Immobilon-P. Monoclonal antibodies to DP1 (1DP06/TFD10 [Labvision]) and DP2 (BC-2 [Sigma] and G-12 [Santa Cruz]) were used at 1 to 2 µg/ml and visualized with a horseradish peroxidase-conjugated sheep anti-mouse immunoglobulin G antibody (Amersham). A rabbit polyclonal antibody against actin (Sigma) was used at a 1:500 dilution and visualized with a horseradish peroxidase-conjugated donkey anti-rabbit immunoglobulin G antibody. The blots were developed with an ECL kit (Amersham) and exposed to autoradiographic film.
|
For array analysis on ES cells, total RNA was extracted from another portion of each ES cell line with TRIzol (Invitrogen) and ca. 3 µg of RNA was reverse transcribed and labeled with [
-32P]dCTP (according to manufacturer instructions). For array analysis on E15.5 organs, total RNA was extracted from the embryonic brains and kidneys dissected from a Dp1-deficient chimera (29C) and a wild-type embryo (ROSA26-LacZ; Dp1+/+) with TRIzol, and ca. 5 µg of RNA was reverse transcribed and labeled with [
-32P]dCTP (according to manufacturer instructions). Hybridization of labeled RNAs was performed by using a GEArray Q series mouse cell cycle gene array (Superarray). Array filters were hybridized overnight at 60°C, washed in 2x SSC (1x SSC is 0.15 M NaCl plus 0.015 M sodium citrate)-1% SDS and then 0.1x SSC-0.5% SDS at 60°C, and exposed to autoradiographic film. (A list of individual cDNAs spotted and their positions is available at http://www.superarray.com.)
| RESULTS |
|---|
|
|
|---|
|
Dp1 is largely dispensable for embryonic development. To determine how well the Dp1-deficient; ROSA26-LacZ ES cell lines contribute to embryonic development, we constructed chimeric embryos, in which wild-type placentas allowed us to bypass the extraembryonic requirement for Dp1. To do this, Dp1-deficient; ROSA26-LacZ ES cells were injected into wild-type donor blastocysts (E3.5) and then reimplanted into the uterine horns of pseudopregnant recipient mice. Chimeric embryos were recovered after various additional lengths of gestation (10 to 15 days) to allow the Dp1-deficient cells to contribute to the normal development of all embryonic tissues. Chimeric embryos were then fixed briefly and subjected to whole-mount analysis with X-Gal staining to visualize the incorporation of the Dp1-deficient; ROSA26-LacZ cells into embryonic tissues, as judged by the extent of blue coloration in the embryo. As a positive control, ROSA26-LacZ embryos were stained with X-Gal in parallel, which leads to entirely blue embryos. As a negative control, uninjected sibling embryos were stained with X-Gal alongside the chimeric embryos. In addition, the Dp1-deficient status of the injected cells was confirmed by regenotyping the unused portion of the ES cells from the day of injection.
Surprisingly, Dp1-deficient chimeric embryos at E12.5 were dark blue, indicating that the Dp1-deficient; ROSA26-LacZ cells successfully contributed to embryonic development (Fig. 2A). This is in sharp contrast to the failed development of Dp1-deficient embryos, which are severely stunted in growth, delayed in development or dead at E11.5 (10). All three Dp1-deficient ES cell lines (2G1, 8G1, and 8G2) contributed well to E12.5 chimeric embryos. This result prompted us to check later gestational embryos by using whole mount X-Gal staining to determine whether Dp1-deficient ES cells could contribute strongly at these time points.
|
Dp1-deficient ES cells are pluripotent. To understand how effectively Dp1-deficient; ROSA26-LacZ ES cells contribute to tissues late in gestation, we performed X-Gal staining on cryosections from Dp1-deficient chimeric embryos at E15.5 and E17.5 to visualize the cytoplasmic deposition of ß-galactosidase in ROSA26-LacZ-marked cells. To visualize both the wild-type and ROSA26-LacZ-marked cells, we counterstained these sections with nuclear fast red. Most tissues showed a predominance of ROSA26-LacZ-marked Dp1-deficient cells, with ample contribution of these cells to all histological cell types and morphological structures in these tissues. Tissues arising from all three germ layers (i.e., endoderm, ectoderm, and mesoderm) are well represented on the list of tissues in which Dp1-deficient; ROSA26-LacZ cells are found in abundance. A sampling of such chimeric tissues at E17.5, including the eye, heart, tongue, kidney, lung, and intestine, is shown in Fig. 3A to F (upper panels). Additional chimeric tissues at E15.5, including the thymus, liver, skin, pancreas, cartilage, and dorsal root ganglion, are shown in Fig. 3G to L (upper panels). The equivalent cryosections from ROSA26-LacZ embryos at E17.5 and E15.5 were stained with X-Gal for comparison (Fig. 3A to L, lower panels).
|
DP2 is not increased in Dp1-deficient tissues. To begin to understand how Dp1-deficient tissues are able to proliferate and develop normally until E15.5 to E17.5, we reasoned that perhaps the expression of DP2 protein is increased to compensate for the loss of Dp1. Although we did not observe a change of DP2 expression in Dp1-deficient ES cells (Fig. 1D), we thought it possible that the differentiation of Dp1-deficient ES cells into various tissues could induce a change in DP2 expression.
To test this notion, we microdissected two sets of tissues from wild-type embryos and two high-contribution Dp1-deficient; ROSA26-LacZ chimeric embryos (29A and 29C) at E15.5. We then performed Western blot analysis for DP1 and DP2 with specific monoclonal antibodies (Fig. 4). First, we compared the expression of DP family members in three tissues (heart, lung, and intestine) that showed a high contribution of Dp1-deficient cells relative to the total population, as judged by the proportion of X-Gal-stained cells in cryosections (Fig. 4A). As expected, we saw little if any expression of DP1 protein in chimeric heart, lung, or intestine in contrast to the expression of DP1 protein in matched wild-type tissues (Fig. 4A, upper panel). Second, we compared the expression of DP family members in five tissues that showed either a high contribution (kidney), patchy contribution (brain and liver), or an undetermined contribution (stomach and bladder) of Dp1-deficient cells relative to the total population, as judged by X-Gal staining in cryosections (Fig. 4B). We observed much less expression of DP1 protein in chimeric brain, kidney, bladder, and stomach compared to the expression of DP1 protein in matched wild-type tissues (Fig. 4B, upper panel). We also observed much less expression of DP1 protein in liver from one of two chimeras examined (29A versus 29C). These Western blotting results suggest that Dp1-deficient cells contribute well even to organs that show uneven X-Gal staining in our cryosection analysis (i.e., brain and fetal liver).
Consistent with our result in Dp1-deficient ES cells (Fig. 1D), we observed no consistent upregulation of DP2 in Dp1-deficient chimeric tissues with actin as a loading control, regardless of the level of DP1 expression in the equivalent wild-type tissue (Fig. 4A and B, middle and lower panels). Thus, the normal development of Dp1-deficient chimeric tissues occurs without obvious compensation in the expression of DP2 protein.
Cell cycle gene expression is unchanged with loss of Dp1. To understand our result that Dp1 deficiency did not compromise embryonic development in most tissues, we determined whether or not Dp1 deficiency changed the expression profile of cell cycle-related genes, many of which are known E2F/DP target genes. To do this, our matched Dp1-deficient ES cell line (2B1), which was used for the bulk of our chimeric analysis, and the wild-type ES cell line (5F4) were grown logarithmically and used for an array analysis, in which the expression of 96 cell cycle-related genes was examined, including cyclins, cyclin-dependent kinases and their inhibitors, E2F/DP, and pRB family members, as well as replication and repair factors. FACS analysis was performed on these ES cell cultures to ensure that both populations were proliferating similarly (73 to 75% in S phase [Fig. 5A ]). The gamma-irradiated embryonic fibroblast feeder cell population necessary to maintain the undifferentiated growth of ES cell colonies was removed prior to both the FACS analysis and array analysis.
|
To determine whether loss of Dp1 compromises the pattern of cell cycle gene expression in more differentiated tissues, we conducted the same array analysis with kidney and brain isolated from an E15.5 Dp1-deficient chimera or an E15.5 wild-type (ROSA26-LacZ) embryo. In either the kidney or the brain, Dp1 deficiency did not alter the overall pattern of cell cycle gene expression from that seen in counterpart wild-type organs (Fig. 5C, kidney, and D, brain). This occurs despite these embryonic tissues being highly proliferative, as judged by the expression of PCNA and Ki67. We note that both the wild-type kidney and brain express little Dp1 mRNA, although we have shown that these wild-type tissues clearly express detectable levels of DP1 protein. In summary, loss of Dp1 in embryonic tissues that have differentiated substantially from their ES cell origin does not change the expression pattern of genes, many of which are E2F targets.
Taken together, the normal development of high contribution Dp1-deficient chimeras and the minor changes in gene expression of cell cycle-related mRNAs in Dp1-deficient ES cells and Dp1-deficient chimeric tissues demonstrate that, surprisingly, the loss of Dp1 is tolerated very well in the embryonic compartment, in contrast to the severe defect we observed previously in the extraembryonic compartment with Dp1 deficiency.
| DISCUSSION |
|---|
|
|
|---|
The normal development of the majority of tissues in the Dp1-deficient chimeric embryos until late gestation (E15.5 to E17.5) is surprising, particularly because the loss of Dp1 so completely impairs the development of the extraembryonic compartment by E8.5 (10). In the trophectoderm lineage, loss of Dp1 lowers the number of precursor cells and inhibits the rate of DNA replication in extraembryonic cell types arising from the trophectoderm. The latter effect is likely due to the known role of E2F/DP complexes in the induction of factors important for the initiation and also the execution of S phase. Extrapolating this mechanism to the embryonic compartment, we had expected to identify numerous tissues in which the loss of Dp1 compromised proliferation and, thus, normal development. However, loss of Dp1 is apparently well tolerated in the embryo once the extraembryonic requirement for Dp1 is bypassed. Consistent with this result is our previous observation that morphologically abnormal Dp1-deficient embryos at E8.5 showed comparable levels of bromodeoxyuridine incorporation in the soma as wild-type sibling embryos despite the clear failure of bromodeoxyuridine incorporation in the extraembryonic compartments (10).
Four possibilities for Dp1 function in the embryo proper are suggested by the normal development of the majority of tissues in Dp1-deficient chimeras until late gestation, despite the death of purely Dp1-deficient embryos before mid-gestation. First, Dp1 may have no role in the embryo proper. This seemed unlikely given the high levels of detectable DP1 protein and RNA in embryonic tissues and its demonstrated role in DNA replication in the extraembryonic tissues (10) but is now a possibility. Second, E2F/DP family activity may not be necessary for normal development in the embryo proper. This is also unlikely given the detectable levels of DP1 and DP2 in embryonic tissues, the known role of E2F/DP complexes in the G1/S transition, and the demonstrated requirement of E2F1-3 for proliferation of primary mouse embryonic fibroblasts (25). Furthermore, we detected no obvious change in the expression of cell cycle-related mRNAs (many of which are E2F/DP target genes) with Dp1 deficiency (Fig. 5), suggesting that E2F/DP function is still optimal in highly proliferating Dp1-deficient ES cells, which we have clearly demonstrated are pluripotent, and in differentiated embryonic tissues. However, loss of Dp1 might be tolerated by compromising both transcriptionally active and repressive E2F/DP complexes simultaneously, in a manner analogous to that in Drosophila, where a single E2F/DP complex (dE2F1/dDP) activates transcription and a single E2F/DP complex (dE2F2/dDP) represses transcription. Although loss of dE2F1 results in abnormal development, the simultaneous inactivation of both dE2F1 and dE2F2 leads to normal development at least until the late pupal stage (6). In addition, loss of dE2F1 leads to larval lethality and growth retardation, but loss of dDP leads to later pupal lethality with no growth retardation (20.a), suggesting that loss of activating and repressive dE2F/dDP complexes does not completely block embryonic development.
Third, DP2 may compensate for the loss of Dp1 in the embryo proper subsequent to its inactivation. An increased level of DP2 in Dp1-deficient cells or tissues also would have supported the notion that DP2 replaced DP1 function; however, the static levels of DP2 protein and Dp2 RNA that we detected in the absence of Dp1 actually does not argue against any of the three possibilities. A search of the NCBI mouse genome database does not reveal the existence of any additional DP family members that might have suggested another route of compensation. Therefore, the unchanged levels of Dp2 mRNA and DP2 protein in the absence of Dp1 suggests that a low level of DP2 expression is sufficient for maintaining E2F/DP activity and thus proliferation in the embryo proper. The simultaneous inactivation of Dp1 and Dp2 in the embryo proper will test this hypothesis directly, and such experiments with the conditional knockout allele of Dp1 are under way.
The fourth and last possibility is that Dp1 is required for the correct development of embryonic tissues, but this requirement is masked in the Dp1-deficient chimeras by the presence of a small population of wild-type embryonic cells that rescue chimeric development in a non-cell-autonomous manner. Conditional inactivation of Dp1 throughout the embryo proper at the epiblast stage by using Cre/loxP-mediated recombination or the construction of tetraploid embryos with Dp1-deficient ES cells will address this possibility.
Interestingly, conditional inactivation of Rb and tetraploid rescue experiments have recently been used to demonstrate that Rb-deficiency results in increased apoptosis and embryonic lethality by compromising the development of the placenta in mid-gestation (2, 24). Once this placental defect involving hyper-proliferation of labyrinthine trophoblast cells is bypassed, surprisingly normal development occurs in most embryonic tissues despite Rb deficiency (14, 23). Conditional inactivation of Rb specifically compromises the development of the brain, muscle, and lens in the embryo, sites where ectopic proliferation is observed (3, 13, 15). Furthermore, the simultaneous inactivation of cyclins E1 and E2 results in mid-gestational embryonic death, due to abnormal development of the placenta (7, 18). In this case, bypassing the endoreduplication defect of trophoblast giant cells in the placenta through tetraploid rescue experiments results in the normal development of late-gestational cyclin E1/2-deficient embryos. In contrast to the placental requirement for Dp1, Rb, or cyclin E1/E2, the loss of Cdk2 has recently been shown to be dispensable for normal embryonic development, although it is required for meiosis and fertility (1, 17).
Thus, there are striking requirements for Dp1, Rb, and cyclins E1/2 in the extraembryonic compartment, whereas the requirements for these genes in the embryo proper are really quite limited. Understanding the nature of the requirements for these key cell cycle regulators specifically in the trophectoderm-derived lineages will be the focus of further study. Finally, discerning how the embryo develops so well in the absence of these cell cycle regulators is of great interest and will undoubtedly require a revision of current cell cycle paradigms.
| ACKNOWLEDGMENTS |
|---|
V.C. is supported by a fellowship from the American-Italian Cancer Foundation, and L.Y. is supported by funds from the Pew Scholars Program in the Biomedical Sciences and the NIH-NCI (R01-CA79646).
| FOOTNOTES |
|---|
Present address: National Institutes of Health/NICHD, Bethesda, MD 20892. ![]()
| REFERENCES |
|---|
|
|
|---|
2. de Bruin, A., L. Wu, H. I. Saavedra, P. Wilson, Y. Yang, T. J. Rosol, M. Weinstein, M. L. Robinson, and G. Leone. 2003. Rb function in extraembryonic lineages suppresses apoptosis in the CNS of Rb-deficient mice. Proc. Natl. Acad. Sci. USA 100:6546-6551.
3. Ferguson, K. L., J. L. Vanderluit, J. M. Hebert, W. C. McIntosh, E. Tibbo, J. G. MacLaurin, D. S. Park, V. A. Wallace, M. Vooijs, S. K. McConnell, and R. S. Slack. 2002. Telencephalon-specific Rb knockouts reveal enhanced neurogenesis, survival and abnormal cortical development. EMBO J. 21:3337-3346.[CrossRef][Medline]
4. Field, S. J., F. Y. Tsai, F. Kuo, A. M. Zubiaga, W. G. Kaelin, Jr., D. M. Livingston, S. H. Orkin, and M. E. Greenberg. 1996. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell 85:549-561.[CrossRef][Medline]
5. Friedrich, G., and P. Soriano. 1991. Promoter traps in embryonic stem cells: a genetic screen to identify and mutate developmental genes in mice. Genes Dev. 5:1513-1523.
6. Frolov, M. V., D. S. Huen, O. Stevaux, D. Dimova, K. Balczarek-Strang, M. Elsdon, and N. J. Dyson. 2001. Functional antagonism between E2F family members. Genes Dev. 15:2146-2160.
7. Geng, Y., Q. Yu, E. Sicinska, M. Das, J. E. Schneider, S. Bhattacharya, W. M. Rideout, R. T. Bronson, H. Gardner, and P. Sicinski. 2003. Cyclin E ablation in the mouse. Cell 114:431-443.[CrossRef][Medline]
8. Humbert, P. O., C. Rogers, S. Ganiatsas, R. L. Landsberg, J. M. Trimarchi, S. Dandapani, C. Brugnara, S. Erdman, M. Schrenzel, R. T. Bronson, and J. A. Lees. 2000. E2F4 is essential for normal erythrocyte maturation and neonatal viability. Mol. Cell 6:281-291.[CrossRef][Medline]
9. Humbert, P. O., R. Verona, J. M. Trimarchi, C. Rogers, S. Dandapani, and J. A. Lees. 2000. E2f3 is critical for normal cellular proliferation. Genes Dev. 14:690-703.
10. Kohn, M. J., R. T. Bronson, E. Harlow, N. J. Dyson, and L. Yamasaki. 2003. Dp1 is required for extra-embryonic development. Development 130:1295-1305.
11. Li, F. X., J. W. Zhu, C. J. Hogan, and J. DeGregori. 2003. Defective gene expression, S phase progression, and maturation during hematopoiesis in E2F1/E2F2 mutant mice. Mol. Cell. Biol. 23:3607-3622.
12. Lindeman, G. J., L. Dagnino, S. Gaubatz, Y. Xu, R. T. Bronson, H. B. Warren, and D. M. Livingston. 1998. A specific, nonproliferative role for E2F-5 in choroid plexus function revealed by gene targeting. Genes Dev. 12:1092-1098.
13. Lipinski, M. M., K. F. Macleod, B. O. Williams, T. L. Mullaney, D. Crowley, and T. Jacks. 2001. Cell-autonomous and non-cell-autonomous functions of the Rb tumor suppressor in developing central nervous system. EMBO J. 20:3402-3413.[CrossRef][Medline]
14. Maandag, E. C., M. van der Valk, M. Vlaar, C. Feltkamp, J. O'Brien, M. van Roon, N. van der Lugt, A. Berns, and H. te Riele. 1994. Developmental rescue of an embryonic-lethal mutation in the retinoblastoma gene in chimeric mice. EMBO J. 13:4260-4268.[Medline]
15. MacPherson, D., J. Sage, D. Crowley, A. Trumpp, R. T. Bronson, and T. Jacks. 2003. Conditional mutation of Rb causes cell cycle defects without apoptosis in the central nervous system. Mol. Cell. Biol. 23:1044-1053.
16. Nagy, A., M. Gertsenstein, K. Vintersten, and R. Behringer. 2003. Manipulating the mouse embryo: a laboratory manual, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
17. Ortega, S., I. Prieto, J. Odajima, A. Martin, P. Dubus, R. Sotillo, J. L. Barbero, M. Malumbres, and M. Barbacid. 2003. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat. Genet. 35:25-31.[CrossRef][Medline]
18. Parisi, T., A. R. Beck, N. Rougier, T. McNeil, L. Lucian, Z. Werb, and B. Amati. 2003. Cyclins E1 and E2 are required for endoreplication in placental trophoblast giant cells. EMBO J. 22:4794-4803.
19. Rempel, R. E., M. T. Saenz-Robles, R. Storms, S. Morham, S. Ishida, A. Engel, L. Jakoi, M. F. Melhem, J. M. Pipas, C. Smith, and J. R. Nevins. 2000. Loss of E2F4 activity leads to abnormal development of multiple cellular lineages. Mol. Cell 6:293-306.[CrossRef][Medline]
20. Robertson, E. J. (ed.). 1987. Teratocarcinomas and embryonic stem cells: a practical approach. IRL Press Limited, Oxford, England.
20. Royzman, I. A. J. Whittaker, and T. L. Orr-Weaver. 1997. Mutations in Drosophila DP and E2F distinguish G1-S progression from an associated transcriptional program. Genes Dev. 11:1999-2011.
21. Storre, J., H. P. Elsasser, M. Fuchs, D. Ullmann, D. M. Livingston, and S. Gaubatz. 2002. Homeotic transformations of the axial skeleton that accompany a targeted deletion of E2f6. EMBO Rep. 3:695-700.[CrossRef][Medline]
22. Trimarchi, J. M., and J. A. Lees. 2002. Sibling rivalry in the E2F family. Nat. Rev. Mol. Cell. Biol. 3:11-20.[CrossRef][Medline]
23. Williams, B. O., E. M. Schmitt, L. Remington, R. T. Bronson, D. M. Albert, R. A. Weinberg, and T. Jacks. 1994. Extensive contribution of Rb-deficient cells to adult chimeric mice with limited histopathological consequences. EMBO J. 13:4251-4259.[Medline]
24. Wu, L., A. de Bruin, H. Saavedra, S. M., A. Trimboli, Y. Yang, J. Opavska, P. Wilson, J. C. Thompson, M. C. Ostrowski, T. J. Rosol, L. A. Woollett, M. Weinstein, J. C. Cross, M. L. Robinson, and G. Leone. 2003. Extra-embryonic function of Rb is essential for embryonic development and viability. Nature 421:942-947.[CrossRef][Medline]
25. Wu, L., C. Timmers, B. Maiti, H. I. Saavedra, L. Sang, G. T. Chong, F. Nuckolls, P. Giangrande, F. A. Wright, S. J. Field, M. E. Greenberg, S. Orkin, J. R. Nevins, M. L. Robinson, and G. Leone. 2001. The E2F1-3 transcription factors are essential for cellular proliferation. Nature 414:457-462.[CrossRef][Medline]
26. Yamasaki, L. 2003. Role of the Rb tumor suppressor in cancer, p. 209-239. In D. A. Frank (ed.), Signal transduction in cancer. Kluwer Academic Publishers, Boston, Mass.
27. Yamasaki, L., T. Jacks, R. Bronson, E. Goillot, E. Harlow, and N. J. Dyson. 1996. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell 85:537-548.[CrossRef][Medline]
28. Zambrowicz, B. P., A. Imamoto, S. Fiering, L. A. Herzenberg, W. G. Kerr, and P. Soriano. 1997. Disruption of overlapping transcripts in the ROSA beta geo 26 gene trap strain leads to widespread expression of ß-galactosidase in mouse embryos and hematopoietic cells. Proc. Natl. Acad. Sci. USA 94:3789-3794.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|